Back to Authors

Muñoz, David G.

0000-0003-0957-6244

A5072024709 | I1297363086

Mayo Clinic

St. Michael's Hospital

Citations 9

Biomarker‐Based Approach to α‐Synucleinopathies: Lessons from Neuropathology

Movement Disorders | October 3, 2024 | Volume: 39 | Issue: 12 | Pages: 2173-2179

10.1002/mds.30028 | PMID 39360851

Immunohistochemical expression of PTTG in brain tumors

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.706.44

Pituitary tumor transforming gene (PTTG) plays a role in many cellular processes. PTTG overexpression is seen in several tumor types and correlates with survival time/recurrence. We evaluated PTTG expression in various types of brain tumors (n=94). Immunohistochemistry was performed using a monoclonal PTTG antibody (DCS‐280, Abcam;Cambridge, MA) and the streptavidin‐biotin‐peroxidase complex method. The intensity of PTTG immunoreactivity was evaluated semi‐quantitatively on a 0‐4 scale. PTTG expression was evident in most tumor cells and was predominantly nuclear. In glial tumors, PTTG immunoreactivity was higher in glioblastomas (IV), anaplastic oligoastrocytomas (III), anaplastic oligodendrogliomas (III), oligoastrocytomas (II), oligodendrogliomas (II), and pilocytic astrocytomas (I) (range: 3.1–3.5), whereas notably lower PTTG was seen in myxopapillary ependymomas (I) and ependymomas (II) (1.5 & 1.6). In non‐glial tumors, hemangiopericytomas and schwannomas had higher PTTG score (3.4), than meningiomas (2.3). Thus, it appears that PTTG expression is not associated with tumor grade, but rather with tumor type, the most striking difference being between ependymomas and other glial tumors. PTTG may be a valuable therapy target in some brain tumors. Acknowledgments Authors thank the Jarislowsky Foundation and the Lloyd‐Carr‐Harris Foundation for their generous support.
In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease

Neurology | August 3, 2020 | Volume: 95 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000010404 | PMID 32747521

Imaging and diagnostic advances for intracranial meningiomas

Neuro-Oncology | October 18, 2018 | Volume: 21 | Issue: Supplement_1 | Pages: i44-i61

10.1093/neuonc/noy143 | PMID 30649491

Advances in multidisciplinary therapy for meningiomas

Neuro-Oncology | September 17, 2018 | Volume: 21 | Issue: Supplement_1 | Pages: i18-i31

10.1093/neuonc/noy136 | PMID 30649489

Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4)

Journal of Neuropathology & Experimental Neurology | August 13, 2018 | Volume: 77 | Issue: 9 | Pages: 793-802

10.1093/jnen/nly056 | PMID 30107604

Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson’s Disease and Control Subjects

Journal of Parkinson’s Disease | September 2, 2016 | Volume: 6 | Issue: 4 | Pages: 761-770

10.3233/jpd-160888 | PMID 27589538

Background: Conflicting results from studies of Lewy-type α−synucleinopathy (LTS) in colonic biopsies of subjects with Parkinson’s disease (PD) prompted a two-part multicenter assessment. The first assessment, now published (Acta Neuropathol Commun 4 : 35, 2016), examined archived colonic biopsies and found that none of the tested methods was adequately sensitive or specific. Objective: As the amount of nervous tissue in typical colonic biopsies may be insufficient, and the clinical diagnosis of PD not completely accurate, the objective of the current study was to use instead full-thickness sections of sigmoid colon from autopsy-proven PD and normal subjects. Methods: Seven different immunohistochemical (IHC) methods were used, employing five different primary antibodies and four different combinations of epitope exposure and signal development protocols. Specific staining was defined as being restricted to morphological features consistent with neuronal elements. Stained slides from each subject were independently categorized as being positive or negative for LTS, and their density semi-quantitatively graded, by four raters blinded to diagnosis. Results: Agreement and mean diagnostic performance varied markedly between raters. With the two most accurate raters, 5 methods achieved diagnostic accuracies of 70% or greater; one method had 100% accuracy and 100% inter-rater agreement. The submucosa had the highest prevalence of pathological LTS staining, followed by the muscularis and mucosa. Conclusions: The major conclusion of this study is that, when sufficient submucosa and LTS is present, and when specific staining is defined as being consistent with neuronal morphology, adequately-trained raters may reliably distinguish PD colon from control using suitable IHC methods.
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype

Neurology | May 14, 2012 | Volume: 56 | Issue: 12 | Pages: 1702-1706

10.1212/wnl.56.12.1702 | PMID 11425937

S4‐04‐01: Frontotemporal Dementia With FUS Pathology

Alzheimer's & Dementia | January 7, 2010 | Volume: 5 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2009.07.128